Duty: Memoirs of a Secretary at War. Rpt. ed: Vintage; 2015.
69. National Center for Injury Prevention and Control. Report to Congress on Mild Traumatic Brain Injury in the United States: Steps to Prevent a Serious Public Health Problem. Centers for Disease Control and Prevention; September 2003; National Center for Injury Prevention and Control. Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation. Centers for Disease Control and Prevention; 2015; The CDC, NIH, DoD, and VA Leadership Panel. Report to Congress on Traumatic Brain Injury in the United States: Understanding the Public Health Problem among Current and Former Military Personnel. Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Department of Defense (DoD), and the Department of Veterans Affairs (VA); 2013.
70. McCrea M. Mild Traumatic Brain Injury and Postconcussion Syndrome: The New Evidence for Diagnosis and Treatment. Oxford University Press; 2008; Mac Donald CL, Johnson AM, Cooper D, et al. Detection of blastrelated traumatic brain injury in U.S. military personnel. New England Journal of Medicine. 2011;364(22):2091–2100; Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancet Neurology. 2015;14(5):506–517; Andrews PJD, Sinclair HL, Rodriguez A, et al. Hypothermia for intracranial hypertension after traumatic brain injury. New England Journal of Medicine. 2015;373(25):2403–2412.
71. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurology. 2017;16(12):987-1048.
72. Mission and goals. National Institutes of Health. www.nih.gov/about-nih/what-we-do/mission-goals. Updated July 27, 2017. Accessed March 30, 2019.
73. Marar M, McIlvain NM, Fields SK, Comstock RD. Epidemiology of concussions among United States high school athletes in 20 sports. American Journal of Sports Medicine. 2012;40(4):747–755; Lincoln AE, Caswell SV, Almquist JL, Dunn RE, Norris JB, Hinton RY. Trends in concussion incidence in high school sports: a prospective 11-year study. American Journal of Sports Medicine. 2011;39(5):958–963; Hootman JM, Dick R, Agel J. Epidemiology of collegiate injuries for 15 sports: summary and recommendations for injury prevention initiatives. Journal of Athletic Training. 2007;42(2):311–319.
74. Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189.
75. Accelerating Medicines Partnership (AMP): Parkinson’s disease. US Department of Health & Human Services. www.nih.gov/research-training/accelerating-medicines-partnership-amp/parkinsons-disease. Updated October 26, 2018. Accessed February 8, 2019.
76. Alzheimer’s and dementia: facts and figures. Alzheimer’s Association. www.alz.org/alzheimers-dementia/facts-figures. Accessed February 8, 2019.
77. Pfizer ends research for new Alzheimer’s, Parkinson’s drugs. Reuters. January 7, 2018. www.reuters.com/article/us-pfizer-alzheimers/pfizer-ends-research-for-new-alzheimers-parkinsons-drugs-idUSKBN1EW0TN. Accessed January 4, 2019.
78. Dunn A. Pfizer, Bain Capital launch neuroscience company backed with $350M. BioPharma Dive. October 23, 2018. www.biopharmadive. com/news/pfizer-bain-capital-neuroscience-Cerevel/540359. Accessed February 8, 2019.
79. Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174–189.
80. American Parkinson Disease Association. www.apdaparkinson.org/ about-apda. Accessed March 30, 2019.
81. Brian Grant Foundation. https://briangrant.org. Accessed March 30, 2019.
82. Parkinsons Foundation 2017 Annual Report. Parkinson’s Foundation; 2017.
83. Impact of the Ice Bucket Challenge. ALS Association. www.alsa.org/ fight-als/ibc-infographic.html. Accessed February 8, 2019.
84. ACT UP New York. www.actupny.org. Accessed March 30, 2019.
85. ParkinsonNet. www.parkinsonnet.info. Accessed January 5, 2019.
86. Okun MS, Ramirez-Zamora A, Foote KD. Neuromedicine service and science hub model. JAMA Neurology. 2018;75(3):271–272.
87. Bloem BR, Rompen L, de Vries NM, Klink A, Munneke M, Jeurissen P. ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands. Health Affairs. 2017;36:1987–1996.
88. van der Kolk NM, de Vries NM, Penko AL, et al. A remotely supervised home-based aerobic exercise programme is feasible for patients with Parkinson’s disease: results of a small randomised feasibility trial. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(9):1003.
89. Szanton SL, Leff B, Wolff JL, Roberts L, Gitlin LN. Home-based care program reduces disability and promotes aging in place. Health Affairs. 2016;35(9):1558–1563.
90. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson’s disease using the minimum data set. Parkinsonism & Related Disorders. 2002;8(5):369–380; Ornstein KA, Leff B, Covinsky KE, et al. Epidemiology of the homebound population in the United States. JAMA Internal Medicine. 2015;175(7):1180–1186; Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson’s disease. Journal of the American Geriatrics Society. 1996;44(4):394–399.
91. Centers for Medicare & Medicaid Services. Medicare & Home Health Care. US Department of Health and Human Services. October 2017. www.medicare.gov/sites/default/files/2018-07/10969-medicare-and-home-health-care.pdf; Your Medicare coverage. Medicare.gov. www. medicare.gov/coverage/home-health-services. Accessed March 30, 2019.
92. Woods B. By 2020, 90 % of world’s population aged over 6 will have a mobile phone: report. The Next Web. November 18, 2014. https:// thenextweb.com/insider/2014/11/18/2020-90-worlds-population-aged-6-will-mobile-phone-report. Accessed October 11, 2018.
93. Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology. 2018;14:285–297.
94. WHO Model List of Essential Medicines. World Health Organization; April 2015.
95. Clinical trial delays: America’s patient recruitment dilemma. Drug Development Technology. July 18, 2012. www.drugdevelopment-technology.com/features/featureclinical-trial-patient-recruitment. Accessed March 30, 2019.
96. Fox Trial Finder. The Michael J. Fox Foundation for Parkinson’s Research. https://foxtrialfinder.michaeljfox.org. Accessed March 30, 2019.
97. Why Clinical Trials? The Michael J. Fox Foundation for Parkinson’s Research.https://files.michaeljfox.org/WhyClinicalTrials.pdf. Accessed January 3, 2019; Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC. Minority enrollment in Parkinson’s disease clinical trials. Parkinsonism & Related Disorders. 2009;15(4):258–262.
98. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data. 2016;3:160011.
99. Fox Insight. The Michael J. Fox Foundation for Parkinson’s Research. https://foxinsight.michaeljfox.org. Accessed January 6, 2019.
100. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Movement Disorders. 2015;30(12):1600–1611.
101. P earson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005;294(20):2618–2622.
102. Weintraub A. How to cover Novartis’ $475K CAR-T drug Kymriah? A “new payment model” is the only way, Express Scripts says. FiercePharma. September 22, 2017. www.fiercepharma.com/financials/ car-t-and-other-gene-therapies-need-new-payment-model-says-express-scripts. Accessed January 6, 2019; Rosenblatt M, Termeer H. Reframing the conversation on drug pricing. NEJM Catalyst. November 20, 2017. https://catalyst.nejm.org/reframing-conversation-drug-pricing. Accessed June 28, 2019.
103. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics. 2003;3(3): 183–205; Hammer PJ. Differential pricing of essential AIDS drugs: markets, politics and public health. Journal of International Economic Law. 2002;5(4):883–912.
Послесловие
1. Pei, S., Kandula, S. & Shaman, J. Differential Effects of Intervention Timing on COVID-19 Spread in the United States. medRxiv. 2020.
2. Pesticide National Synthesis Project: Estimated annual agricultural pesticide use. US Geological Survey,www.water.usgs.gov/nawqa/pnsp/ usage/maps/show_map.php?year=2017& map=PARAQUAT&hilo=H. Updated June 18, 2020, Accessed October 25, 2020.
3. Meyer, B. Update from D.C.: EPA Allows Usage of Hazardous Pesticide
Paraquat to Continue in the U.S.. Michael J, Fox Foundation. October 26, 2020. www.michaeljfox.org/news/update-dc-epa-allows-usage-
hazardous-pesticide-paraquat-continue-us. Accessed November 2, 2020.
4. Martin, J. TOXMAP, federal database allowing public to track U.S. pollution, shut down after 15 years by National Library of Medicine. Newsweek Digital, December 24 2019. www.newsweek.com/ toxmap-federal-database-allowing-public-track-us-pollution-shut-down-after-15-years-trump-1479146. Accessed October 26, 2020.
5. Peters, R., Ee, N., Peters, J., Booth, A., Mudway, I.